Portfolio

Draupnir Bio

Draupnir Bio is founded on the pillars of outstanding protein and carbohydrate chemistry. Its mission is to understand the molecular basis of how disease-risk proteins interact with carbohydrate structures of the vascular glycocalyx, and use this knowledge to develop therapeutics for life-threatening illnesses. The company is a spin out from Aarhus University, Denmark and Max Planck Institute, Potsdam, Germany.
The lead program is a small molecule oral available PCSK9 inhibitor for lowering LDL cholesterol. Its discovery is based on the finding that PCSK9-induced degradation of the LDL receptor requires the interaction of PCSK9 with distinct heparan sulfate structures of the liver glycocalyx. Inhibition of the PCSK9/heparan sulfate interaction protects the LDL receptor and allows it to remove LDL cholesterol from the blood, thereby preventing the progression of ischemic heart disease, the biggest killer worldwide.

Info & Contact

Address

Draupnir Bio ApS
CVR no. 38 54 68 80
Solsikkevej 8
8240 Risskov
Denmark

In portfolio

27. Dec 2018